BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $84 at Oppenheimer
October 28, 2021 6:20 AM EDTOppenheimer analyst Leland Gershell raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $84.00 (from $81.00) while maintaining a Perform rating.
The analyst commented, "Much of 3Q21's revenue lightness ($408.7M vs. our/cons $413.8/435.3M) was attributed to order/shipment timing (Aldurazyme,... More
BioMarin Pharma (BMRN) Tops Q3 EPS by 4c
October 27, 2021 4:10 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $408.7 million versus the consensus estimate of $435.89 million.
GUIDANCE:
BioMarin Pharma sees Q4 2021 revenue of $1.82-1.88 billion, versus the consensus of... More
